RJA
IONS icon

Raymond James & Associates’s Ionis Pharmaceuticals IONS Stock Holding History

Raymond James & Associates’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$902K Sell
22,524
-1,049
-4% -$48.8K ﹤0.01% 2758
2024
Q2 		$1.12M Sell
23,573
-88,981
-79% -$3.65M ﹤0.01% 2549
2024
Q1 		$4.88M Sell
112,554
-71,122
-39% -$3.39M ﹤0.01% 1600
2023
Q4 		$9.29M Sell
183,676
-10,953
-6% -$525K 0.01% 1151
2023
Q3 		$8.83M Buy
194,629
+2,745
+1% +$113K 0.01% 1111
2023
Q2 		$7.87M Sell
191,884
-9,070
-5% -$349K 0.01% 1206
2023
Q1 		$7.18M Sell
200,954
-24,516
-11% -$921K 0.01% 1232
2022
Q4 		$8.52M Sell
225,470
-12,698
-5% -$534K 0.01% 1079
2022
Q3 		$10.5M Sell
238,168
-8,281
-3% -$349K 0.01% 934
2022
Q2 		$9.12M Sell
246,449
-10,277
-4% -$388K 0.01% 1031
2022
Q1 		$9.51M Sell
256,726
-1,259
-0.5% -$41.2K 0.01% 1099
2021
Q4 		$7.85M Sell
257,985
-43,464
-14% -$1.37M 0.01% 1245
2021
Q3 		$10.1M Buy
301,449
+7,511
+3% +$283K 0.01% 1051
2021
Q2 		$11.7M Sell
293,938
-8,137
-3% -$319K 0.01% 988
2021
Q1 		$13.6M Sell
302,075
-4,559
-1% -$254K 0.01% 860
2020
Q4 		$17.3M Sell
306,634
-55,795
-15% -$2.78M 0.02% 681
2020
Q3 		$17.2M Buy
362,429
+9,055
+3% +$503K 0.02% 605
2020
Q2 		$20.8M Sell
353,374
-1,130
-0.3% -$62.9K 0.03% 502
2020
Q1 		$16.8M Sell
354,504
-348,470
-50% -$19.4M 0.03% 519
2019
Q4 		$42.5M Sell
702,974
-29,830
-4% -$1.78M 0.05% 307
2019
Q3 		$43.9M Sell
732,804
-36,156
-5% -$2.36M 0.06% 282
2019
Q2 		$49.4M Sell
768,960
-26,357
-3% -$1.86M 0.07% 258
2019
Q1 		$64.6M Buy
795,317
+11,558
+1% +$746K 0.1% 199
2018
Q4 		$42.4M Sell
783,759
-28,609
-4% -$1.46M 0.07% 243
2018
Q3 		$41.9M Sell
812,368
-24
-0% -$1.13K 0.06% 275
2018
Q2 		$33.9M Buy
812,392
+24,624
+3% +$1.09M 0.06% 319
2018
Q1 		$34.7M Buy
787,768
+10,319
+1% +$524K 0.06% 294
2017
Q4 		$39.1M Buy
777,449
+500
+0.1% +$27.4K 0.07% 255
2017
Q3 		$39.4M Buy
776,949
+10,937
+1% +$573K 0.08% 231
2017
Q2 		$39M Buy
766,012
+31,322
+4% +$1.46M 0.08% 232
2017
Q1 		$29.5M Buy
734,690
+36,128
+5% +$1.62M 0.07% 280
2016
Q4 		$33.4M Buy
698,562
+172,383
+33% +$6.82M 0.09% 230
2016
Q3 		$19.3M Sell
526,179
-6
-0% -$188 0.05% 354
2016
Q2 		$12.3M Buy
526,185
+12,802
+2% +$413K 0.04% 474
2016
Q1 		$20.8M Buy
513,383
+15,409
+3% +$626K 0.07% 297
2015
Q4 		$30.8M Buy
497,974
+11,455
+2% +$618K 0.11% 198
2015
Q3 		$19.7M Buy
486,519
+12,764
+3% +$661K 0.08% 273
2015
Q2 		$27.3M Buy
473,755
+30,601
+7% +$1.95M 0.1% 213
2015
Q1 		$28.2M Buy
443,154
+56,372
+15% +$3.82M 0.12% 172
2014
Q4 		$23.9M Buy
386,782
+139,499
+56% +$6.88M 0.12% 183
2014
Q3 		$9.6M Buy
247,283
+20,616
+9% +$731K 0.06% 370
2014
Q2 		$7.81M Buy
226,667
+33,693
+17% +$1.06M 0.05% 441
2014
Q1 		$8.34M Buy
192,974
+27,021
+16% +$1.31M 0.06% 380
2013
Q4 		$6.61M Buy
165,953
+33,474
+25% +$1.19M 0.05% 423
2013
Q3 		$4.97M Buy
132,479
+12,869
+11% +$384K 0.04% 473
2013
Q2 		$3.21M Buy
+119,610
New +$2.54M 0.03% 588

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

Raymond James & Associates's IONS Position: Q3 2024 in Review

Raymond James & Associates reduced its Ionis Pharmaceuticals (IONS) stake by 4.5% in Q3 2024, selling an estimated $48.8K and leaving 22,524 shares worth $902K. The position accounts for ﹤0.01% of the portfolio, ranked #2758.

Raymond James & Associates first reported a position in IONS in Q2 2013 and has held it in 46 quarters since. The position peaked at $64.6M in Q1 2019. 354 funds tracked by Wall St. Rank hold IONS as of Q3 2024.

  • Raymond James & Associates held 22,524 shares of Ionis Pharmaceuticals worth $902K as of Q3 2024.
  • Raymond James & Associates sold 1,049 Ionis Pharmaceuticals shares in Q3 2024, an estimated $48.8K.
  • Ionis Pharmaceuticals made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2758 holding.
  • Raymond James & Associates first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's Ionis Pharmaceuticals position peaked at $64.6M in Q1 2019.
  • 354 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.